TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19070056
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + Zinc supplementation (20 mg of each day(‐1))
Study: 7488417
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus hydroxyzine hydrochloride (group G/H)
Study: 31607719
Drug: Edaravone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone treatment
Study: 27160841
Drug: ICU Nurse-Physician
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICU Nurse-Physician Questionnaire (ICU N-P-Q) administered to physicians and nurses
Study: 25115761
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH; reviparin)
Study: 9385125
Drug: Beclomethasone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (200 microg twice daily)
Study: 17990465
Drug: Chemotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy of DCF regimen combined with Chinese herbal medicine
Study: 17990465
Drug: Chemotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy of DCF regimen alone
Study: 3001780
Drug: 1‐g marihuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐g marihuana cigarette containing 1.83% delta 9‐tetrahydrocannabinol (THC)
Study: 29616749
Drug: Magnetic therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic therapy: 10 mT, 50 Hz
Study: 29616749
Drug: Placebo magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo magnetic therapy
Study: 23926420
Drug: Intravenous dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dihydroergotamine (IV DHE)
Study: 17158412
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (2.1 g/d)
Study: 9146778
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 3 consecutive days each week
Study: 18685511
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation C (5 probiotics and FOS)
Study: 18685511
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation D (5 probiotics and GOS)
Study: 14525568
Drug: Topical anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-inflammatory gel (NSAID)
Study: 10655976
Drug: Spread enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread enriched with free soyabean-oil sterols (0.8 g/d)
Study: 1304727
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of oral triazolam and 0.75 mg of intrathecal phenylephrine
Study: 6089652
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human interferon-alpha 2 (HuIFN-alpha 2) 10(7) IU/day
Study: 26362259
Drug: Teacher Help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teacher Help for ADHD treatment group
Study: 27374361
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (AlGaAs infrared laser 808 nm)
Study: 27374361
Drug: Mock laser
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock laser therapy (device powered off)
Study: 25140469
Drug: Left internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left internal thoracic artery (LITA) for LAD and free right internal thoracic artery (RITA) for circumflex in Group-1 (G-1)
Study: 22221980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (three monthly workshops promoting healthy behaviors)
Study: 9591766
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on therapy (n=13)
Study: 7611750
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: 250 mg/m2 of l‐leucovorin and 600 mg/m2 of 5‐fluorouracil weekly
Study: 2361638
Drug: Metronidazole tablets
Normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole tablets 500 mg 3 times daily for 10 days
Study: 2361638
Drug: Metronidazole (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (repeated treatments, once or twice)
Study: 58199
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and D.H.E.
Study: 58199
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone and Heparin and D.H.E.
Study: 26053679
Drug: Single-dose antihelminthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antihelminthic treatment with 400 mg albendazole
Study: 10710871
Drug: 0.3% Ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Ofloxacin otic solution (OFLX) 6 drops twice daily
Study: 10710871
Drug: Oral Amoxycillin
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Amoxycillin 500 mg three times daily plus 1% Chloramphenicol ear drop at 3 drops three times daily (AMOX + CRP)
Study: 24664858
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Study: 20671225
Drug: Fluvastatin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin combined with benazepril-valsartan therapy
Study: 20671225
Drug: Benazepril-valsartan therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril-valsartan therapy alone
Study: 19810298
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate powder, equivalent to 20 mg elemental zinc
Study: 12476650
Drug: Paclitaxel-coated stent
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated stent (drug-eluting stent)
Study: 12476650
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-drug-eluting stent)
Study: 2360387
Drug: Lidocaine as
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine as laryngotracheal spray (1 mg/kg BW)
Study: 2360387
Drug: Lidocaine as
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine as transtracheal injection (1 mg/kg BW)
Study: 2360387
Drug: Lidocaine as
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine as intravenous injection (1 mg/kg BW)
Study: 118805
Drug: Hexamethylmelamine (HMM)
Normalized name: HMM
DrugBank: Altretamine (DB00488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hexamethylmelamine (HMM) alone, 300 mg/m2/day x 14 days every 21 days
Study: 118805
Drug: HOM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOM regimen (HMM 200 mg/m2/day x 21 days, vincristine 1.5 mg on Days 1, 8, and 15, mitomycin C 12 mg/m2 once every 6 weeks)
Study: 18050183
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment in group A (G/A genotype)
Study: 18050183
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment in group G (G/G genotype)
Study: 9475818
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate 100 mg
Study: 20100992
Drug: Norepinephrine increase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine increase during phentolamine infusion
Study: 30859184
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg q8h
Study: 3133709
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing regimens
Study: 21324590
Drug: CST plus
Normalized name: dimethiconol (50000 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST plus sertraline
Study: 14527527
Drug: Sertraline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline alone
Study: 17299655
Drug: Perioperative improvements
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative improvements including thorough preoperative haematological checks, administration of inhibitors of fibrinolysis (aprotinin, ε‐aminocaproic acid), minimization of extracorporeal circulation (ECC), and postoperative recovery measures (i.v. iron and recombinant human erythropoietin).
Study: 11721504
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy: intra-nasal corticosteroids)
Study: 25376670
Drug: Tri-length laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon), treated three times a week for a total of 10 sessions.
Study: 25376670
Drug: Tri-length laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon) in patients with low-back pain and leg pain.
Study: 16926581
Drug: Interdisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatment consisting of education, exercise and stretch, goal setting, medication management, and cognitive and behavioral techniques.
Study: 9018388
Drug: Paroxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine and Fluoxetine (SSRIs)
Study: 8276043
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg taken once daily with breakfast
Study: 8276043
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg taken once daily with evening meal
Study: 31749238
Drug: Bexagliflozin 20
Normalized name: bexagliflozin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin 20 mg
Study: 25078372
Drug: scFOS-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS-supplemented formula (4 g/L scFOS)
Study: 25078372
Drug: placebo-supplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-supplemented formula (4 g/L maltodextrins)
Study: 12736485
Drug: hANP (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP (25 microg intracoronary injection + 0.025 microg x kg(‐1) x min(‐1) intravenous infusion for 1 week)
Study: 11705173
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml low‐molecular weight heparin (Group 2)
Study: 11705173
Drug: Compression stockings
Normalized name: Truform Medical Compression Stockings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression stockings and 0.3 ml LMWH (Group 3)
Study: 9140691
Drug: Amlodipine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 20 mg iv (two doses of 10 mg each)
Study: 9140691
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml, two doses)
Study: 24506965
Drug: Low-dose carvedilol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carvedilol combined with candesartan
Study: 16652033
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of abacavir/lamivudine (FDC)
Study: 16652033
Drug: Separate entities
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate entities (abacavir twice daily and lamivudine once daily) (SE)
Study: 12814254
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (vincristine, lomustine, and prednisone or '8-in-1') with involved-field irradiation
Study: 11009150
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose anthelminthic (400 mg albendazole)
Study: 11009150
Drug: Daily iron‐folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron‐folate supplements (36 g iron and 5 mg folate)
Study: 22435991
Drug: ICG-augmented diode
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-augmented diode laser treatment (ICG+DL)
Study: 17217359
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 400 microgram oral misoprostol
Study: 17217359
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 400 microgram oral misoprostol
Study: 8575118
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg and 40 mg
Study: 16494640
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 2.5 mg
Study: 2213283
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors or calcium channel blockers
Study: 31584783
Drug: Kamedis Eczema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kamedis Eczema Therapy Cream (test product)
Study: 31584783
Drug: Vehicle (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (identical test product without botanical combination)
Study: 28566590
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day for men, 15 mg/day for women)
Study: 28566590
Drug: Metformin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (750 mg/day)
Study: 24105252
Drug: Bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate 10 mg (reference)
Study: 24105252
Drug: Bepotastine salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine salicylate 9.64 mg (test)
Study: 8326293
Drug: Pravastatin (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Study: 8326293
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Simvastatin and Pravastatin)
Study: 3732227
Drug: CO measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO measurement demonstration at the beginning of treatment
Study: 3732227
Drug: CO measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO measurement demonstration at the end of treatment (prior to self-reports)
Study: 3732227
Drug: CO measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO measurement demonstration at the end of treatment (subsequent to self-reports)
Study: 8772902
Drug: Isoniazid 10
Normalized name: isoniazid 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 10 mg/kg
Study: 31910916
Drug: Problem Adaptation
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Adaptation Therapy (PATH)
Study: 28223082
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy of Cognitively Impaired Older Adults (ST‐CI)
Study: 10858844
Drug: S‐(+)‐ketamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐(+)‐ketamine (1.5 mg/kg)
Study: 10858844
Drug: ketamine‐racemic mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine‐racemic mixture (3 mg/kg)
Study: 9350068
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of n‐3 PUFA
Study: 9350068
Drug: 0.65 g
Normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g of n‐3 PUFA
Study: 29588127
Drug: Opioid drugs
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid drugs
Study: 25912040
Drug: Experimental soy-based
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental soy-based formula 2 (EF2) containing scFOS (2.5 g/L) and mixed carotenoids
Study: 17923208
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate topical cream
Study: 17923208
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream (placebo)
Study: 28671857
Drug: Escalating dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose MTX with PEG asparaginase without leucovorin rescue
Study: 25981348
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole 5mg/day
Study: 25981348
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole 10mg/day
Study: 25981348
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole 20mg/day
Study: 19216014
Drug: Focused atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused atorvastatin therapy
Study: 17926823
Drug: Rituximab +
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab + Steroid
Study: 14716774
Drug: IFN-alpha-intermittent group
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha-intermittent group (3 MU of IFN-alpha daily for 10 days every month for 6 months, then 3 MU daily for 10 days every 3 months for 18 months)
Study: 14716774
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IFN-alpha therapy)
Study: 9218075
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 750 mg b.d.
Study: 9218075
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. plus amoxycillin 750 mg b.d.
Study: 30926400
Drug: ReHand tablet
Normalized name: Artemisia Rehan Flowering Top
DrugBank: Wormwood (DB14291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReHand tablet application (experimental group)
Study: 18300265
Drug: Double-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo (normal saline) with the same dose and frequency (Arm B)
Study: 15633323
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia (lidocaine 2% adrenaline)
Study: 15633323
Drug: Injection anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthesia
Study: 11734708
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime for 3 days
Study: 11734708
Drug: Topical polymyxin‐bacitracin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polymyxin‐bacitracin for 7 days
Study: 11734708
Drug: Topical polymyxin‐bacitracin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polymyxin‐bacitracin
Study: 9222674
Drug: No submucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No submucosal saline injection
Study: 21545527
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise program (endurance and activity of daily living training, twice a day)
Study: 3117400
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) group, intravesical instillation with 50 mg ADM dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Study: 3117400
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, transurethral resection or transurethral coagulation alone; no drug intervention.
Study: 31609926
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate capsules at a dose of 90 mg (high-dose) daily for 16 weeks
Study: 23392882
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.0 g TAU and 3.2 g BCAA, thrice a day, for 2 weeks prior to and 4 days after exercise
Study: 23392882
Drug: TAU alone
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU alone (2.0 g)
Study: 11137327
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (170 microg/day)
Study: 11137327
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy with higher dose of NETA (350 microg/day)
Study: 8959465
Drug: Minaprine (antidepressant)
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (antidepressant)
Study: 8959465
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or other antidepressants not specified)
Study: 30574790
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose enoxaparin (0.8 mg/kg)
Study: 30194765
Drug: Subtherapeutic levels
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtherapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Study: 18281656
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg PO bid
Study: 18281656
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg PO qid
Study: 18281656
Drug: Celecoxib and
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib and Zileuton at the same doses
Study: 12676601
Drug: Combustion particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combustion particles (1.0 mg/m3) followed by allergen challenge